150 related articles for article (PubMed ID: 23727984)
1. The pathogenic A391E mutation in FGFR3 induces a structural change in the transmembrane domain dimer.
Mudumbi KC; Julius A; Herrmann J; Li E
J Membr Biol; 2013 Jun; 246(6):487-93. PubMed ID: 23727984
[TBL] [Abstract][Full Text] [Related]
2. Characterization of membrane protein interactions in plasma membrane derived vesicles with quantitative imaging Förster resonance energy transfer.
Sarabipour S; Del Piccolo N; Hristova K
Acc Chem Res; 2015 Aug; 48(8):2262-9. PubMed ID: 26244699
[TBL] [Abstract][Full Text] [Related]
3. FGFR3 transmembrane domain interactions persist in the presence of its extracellular domain.
Sarabipour S; Hristova K
Biophys J; 2013 Jul; 105(1):165-71. PubMed ID: 23823235
[TBL] [Abstract][Full Text] [Related]
4. Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles.
Sarabipour S; Hristova K
Biochim Biophys Acta; 2016 Jul; 1858(7 Pt A):1436-42. PubMed ID: 27040652
[TBL] [Abstract][Full Text] [Related]
5. Primary and secondary dimer interfaces of the fibroblast growth factor receptor 3 transmembrane domain: characterization via multiscale molecular dynamics simulations.
Reddy T; Manrique S; Buyan A; Hall BA; Chetwynd A; Sansom MS
Biochemistry; 2014 Jan; 53(2):323-32. PubMed ID: 24397339
[TBL] [Abstract][Full Text] [Related]
6. Multiple consequences of a single amino acid pathogenic RTK mutation: the A391E mutation in FGFR3.
Chen F; Sarabipour S; Hristova K
PLoS One; 2013; 8(2):e56521. PubMed ID: 23437153
[TBL] [Abstract][Full Text] [Related]
7. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation.
Li E; You M; Hristova K
J Mol Biol; 2006 Feb; 356(3):600-12. PubMed ID: 16384584
[TBL] [Abstract][Full Text] [Related]
8. Structure of FGFR3 transmembrane domain dimer: implications for signaling and human pathologies.
Bocharov EV; Lesovoy DM; Goncharuk SA; Goncharuk MV; Hristova K; Arseniev AS
Structure; 2013 Nov; 21(11):2087-93. PubMed ID: 24120763
[TBL] [Abstract][Full Text] [Related]
9. FGFR3 unliganded dimer stabilization by the juxtamembrane domain.
Sarabipour S; Hristova K
J Mol Biol; 2015 Apr; 427(8):1705-14. PubMed ID: 25688803
[TBL] [Abstract][Full Text] [Related]
10. The A391E mutation enhances FGFR3 activation in the absence of ligand.
Chen F; Degnin C; Laederich M; Horton WA; Hristova K
Biochim Biophys Acta; 2011 Aug; 1808(8):2045-50. PubMed ID: 21536014
[TBL] [Abstract][Full Text] [Related]
11. NMR-based approach to measure the free energy of transmembrane helix-helix interactions.
Mineev KS; Lesovoy DM; Usmanova DR; Goncharuk SA; Shulepko MA; Lyukmanova EN; Kirpichnikov MP; Bocharov EV; Arseniev AS
Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):164-72. PubMed ID: 24036227
[TBL] [Abstract][Full Text] [Related]
12. Role of dimerization efficiency of transmembrane domains in activation of fibroblast growth factor receptor 3.
Volynsky PE; Polyansky AA; Fakhrutdinova GN; Bocharov EV; Efremov RG
J Am Chem Soc; 2013 Jun; 135(22):8105-8. PubMed ID: 23679838
[TBL] [Abstract][Full Text] [Related]
13. Pathogenic Cysteine Removal Mutations in FGFR Extracellular Domains Stabilize Receptor Dimers and Perturb the TM Dimer Structure.
Sarabipour S; Hristova K
J Mol Biol; 2016 Oct; 428(20):3903-3910. PubMed ID: 27596331
[TBL] [Abstract][Full Text] [Related]
14. Direct assessment of the effect of the Gly380Arg achondroplasia mutation on FGFR3 dimerization using quantitative imaging FRET.
Placone J; Hristova K
PLoS One; 2012; 7(10):e46678. PubMed ID: 23056398
[TBL] [Abstract][Full Text] [Related]
15. FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism.
He L; Shobnam N; Wimley WC; Hristova K
J Biol Chem; 2011 Apr; 286(15):13272-81. PubMed ID: 21324899
[TBL] [Abstract][Full Text] [Related]
16. Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization.
Del Piccolo N; Placone J; Hristova K
Biophys J; 2015 Jan; 108(2):272-8. PubMed ID: 25606676
[TBL] [Abstract][Full Text] [Related]
17. The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization.
Chen L; Placone J; Novicky L; Hristova K
Sci Signal; 2010 Nov; 3(150):ra86. PubMed ID: 21119106
[TBL] [Abstract][Full Text] [Related]
18. A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome.
Toydemir RM; Brassington AE; Bayrak-Toydemir P; Krakowiak PA; Jorde LB; Whitby FG; Longo N; Viskochil DH; Carey JC; Bamshad MJ
Am J Hum Genet; 2006 Nov; 79(5):935-41. PubMed ID: 17033969
[TBL] [Abstract][Full Text] [Related]
19. Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers.
You M; Spangler J; Li E; Han X; Ghosh P; Hristova K
Biochemistry; 2007 Oct; 46(39):11039-46. PubMed ID: 17845056
[TBL] [Abstract][Full Text] [Related]
20. A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors.
Del Piccolo N; Sarabipour S; Hristova K
J Biol Chem; 2017 Jan; 292(4):1288-1301. PubMed ID: 27927983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]